Kristen rat sarcoma virus (KRAS) G12F-positive non-small cell lung cancer mimicking KRAS G12C positivity: A case report.
AMOY
G12C
G12F
KRAS
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
09
11
2023
received:
11
10
2023
accepted:
11
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Searching for driver gene alteration is a prerequisite for chemotherapy of non-small cell lung cancer. Due to its high sensitivity and concordance rate, the Amoy Dx Pan Lung Cancer PCR panel has been approved and is widely used in Japan. In this report, we describe a case in which a positive result for Kristen rat sarcoma virus (KRAS) exon2 p.G12F, a rare KRAS mutation, may have led to a false-positive result for KRAS exon2 p.G12C on AMOY. Genetic analysis in this case was performed by LC-SCRUM-Asia.
Identifiants
pubmed: 38010032
doi: 10.1111/1759-7714.15171
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192-iv237. https://doi.org/10.1093/annonc/mdy275
Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(9):911-919. Available from: https://doi.org/10.1200/JCO.2017.76.7293
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497-530. Available from: https://jnccn.org/view/journals/jnccn/20/5/article-p497.xml
Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640-649. https://doi.org/10.1056/NEJMoa1916623
Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Cancer Res. 2020;80(14):2969-2974. Available from: https://doi.org/10.1158/0008-5472.CAN-19-3682
Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J, Kohno T. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107(6):713-720. Available from: https://doi.org/10.1111/cas.12941
Tamiya Y, Matsumoto S, Zenke Y, Yoh K, Ikeda T, Shibata Y, et al. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung Cancer. 2023;176:103-111. https://doi.org/10.1016/j.lungcan.2022.12.019
Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. https://doi.org/10.1056/NEJMoa2103695
Vaclova T, Chakraborty A, Sherwood J, Ross S, Carroll D, Barrett JC, et al. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Sci Rep. 2022;12(1):2699. https://doi.org/10.1038/s41598-022-06369-3
Kunimasa K, Matsumoto S, Kawamura T, Inoue T, Tamiya M, Kanzaki R, et al. Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer. 2023;179:107190. https://doi.org/10.1016/j.lungcan.2023.107190
COSMIC. ver 98. Available from: https://cancer.sanger.ac.uk/cosmic
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48(6):607-616. https://doi.org/10.1038/ng.3564
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173(2):291-304. https://doi.org/10.1016/j.cell.2018.03.022
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596-609. Available from: https://doi.org/10.1158/2159-8290.CD-16-1337